FilingReader Intelligence
Hubei Biocause Pharmaceutical to delist from Shenzhen exchange
August 13, 2025 at 11:59 AM UTC•By FilingReader AI
Hubei Biocause Pharmaceutical announced its intention to delist from the Shenzhen Stock Exchange due to business restructuring and uncertainties.
The company will transition to the National Equities Exchange and Quotations following the voluntary delisting.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
SZSE:000627•Shenzhen Stock Exchange
News Alerts
Get instant email alerts when Hubei Biocause Pharmaceutical publishes news
Free account required • Unsubscribe anytime